Hot Topics: Depression in Individuals With Psoriasis and Psoriatic Arthritis

被引:1
作者
Goel, Niti [1 ,2 ]
Wallace, Elizabeth B. [3 ]
Lindsay, Christine [4 ]
机构
[1] Duke Univ Sch Med, Caduceus Biomed Consulting LLC, Durham, NC USA
[2] Duke Univ Sch Med, Dept Med, Div Rheumatol, Durham, NC USA
[3] Cherry Hills Dermatol, Englewood, CO USA
[4] Patient Res Partner, Prosper, TX USA
关键词
comorbidity; depression; GRAPPA; psoriasis; psoriatic arthritis; PATIENT-REPORTED OUTCOMES; SEVERE PLAQUE PSORIASIS; QUALITY-OF-LIFE; ORAL PHOSPHODIESTERASE-4 INHIBITOR; TO-SEVERE PSORIASIS; PHASE-III; DOUBLE-BLIND; NAIVE PATIENTS; MODERATE; PLACEBO;
D O I
10.3899/jrheum.2024-0362
中图分类号
R5 [内科学];
学科分类号
1002 ; 100201 ;
摘要
Psoriasis and psoriatic arthritis are associated with an increased risk of mental health conditions such as depression and anxiety. People with psoriatic disease (PsD) are also more likely to die by suicide than those without. Mood disorders affect people with PsD in a multitude of ways, such as in effectiveness of care, response to treatment, remission rates, and quality of life. Although the links between PsD and mental health conditions have not been fully elucidated, this review will highlight recent studies investigating shared biologic mechanisms between depression and PsD. Since mental health disorders can be assessed and treated effectively, dermatologists and rheumatologists should be aware of the mental health burden in individuals with PsD to accomplish the following: (1) educate their patients with PsD about this association, (2) screen for mental health conditions on an ongoing basis in their clinical practice, (3) refer their patients with PsD to a mental health professional when needed, and (4) ensure selection of a safe PsD treatment in the setting of comorbid mental health disease. Finally, important treatment considerations for individuals with PsD and depression are reviewed. This topic was presented at the Group for Research and Assessment of Psoriasis and Psoriatic Arthritis (GRAPPA) 2023 annual meeting.
引用
收藏
页码:43 / 50
页数:8
相关论文
共 88 条
[21]   Effect of Certolizumab Pegol on Multiple Facets of Psoriatic Arthritis as Reported by Patients: 24-Week Patient-Reported Outcome Results of a Phase III, Multicenter Study [J].
Gladman, D. ;
Fleischmann, R. ;
Coteur, G. ;
Woltering, F. ;
Mease, P. J. .
ARTHRITIS CARE & RESEARCH, 2014, 66 (07) :1085-1092
[22]   Anxiety and depression in patients with moderate-to-severe psoriasis and comparison of change from baseline after treatment with guselkumab vs. adalimumab: results from the Phase 3 VOYAGE 2 study [J].
Gordon, K. B. ;
Armstrong, A. W. ;
Han, C. ;
Foley, P. ;
Song, M. ;
Wasfi, Y. ;
You, Y. ;
Shen, Y. -K. ;
Reich, K. .
JOURNAL OF THE EUROPEAN ACADEMY OF DERMATOLOGY AND VENEREOLOGY, 2018, 32 (11) :1940-1949
[23]   Ixekizumab improves patient-reported outcomes up to 52 weeks in bDMARD-naive patients with active psoriatic arthritis (SPIRIT-P1) [J].
Gottlieb, Alice B. ;
Strand, Vibeke ;
Kishimoto, Mitsumasa ;
Mease, Philip ;
Thaci, Diamant ;
Birt, Julie ;
Lee, Chin H. ;
Shuler, Catherine L. ;
Lin, Chen-Yen ;
Gladman, Dafna D. .
RHEUMATOLOGY, 2018, 57 (10) :1777-1788
[24]   Impact of Ixekizumab Treatment on Depressive Symptoms and Systemic Inflammation in Patients with Moderate-to-Severe Psoriasis: An Integrated Analysis of Three Phase 3 Clinical Studies [J].
Griffiths, Christopher E. M. ;
Fava, Maurizio ;
Miller, Andrew H. ;
Russell, James ;
Ball, Susan G. ;
Xu, Wen ;
Acharya, Nayan ;
Rapaport, Mark Hyman .
PSYCHOTHERAPY AND PSYCHOSOMATICS, 2017, 86 (05) :260-267
[25]   Incidence rates of suicidal behaviors and treated depression in patients with and without psoriatic arthritis using the Clinical Practice Research Datalink [J].
Hagberg, Katrina Wilcox ;
Li, Lin ;
Peng, Michael ;
Shah, Kamal ;
Paris, Maria ;
Jick, Susan .
MODERN RHEUMATOLOGY, 2016, 26 (05) :774-779
[26]   Common Fundamentals of Psoriasis and Depression [J].
HOLSKEN, Stefanie ;
KREFTING, Frederik ;
SCHEDLOWSK, Manfred, I ;
SONDERMANN, Wiebke .
ACTA DERMATO-VENEREOLOGICA, 2021, 101
[27]   Effects of Intravenous Golimumab on Health-Related Quality of Life in Patients With Psoriatic Arthritis: 24-Week Results of the GO-VIBRANT Trial [J].
Husni, M. Elaine ;
Kavanaugh, Arthur ;
Chan, Eric K. H. ;
Peterson, Steven ;
Li, Nan ;
Hsia, Elizabeth C. ;
Kim, Lilianne ;
Lo, Kim Hung ;
Harrison, Diane D. ;
Han, Chenglong .
VALUE IN HEALTH, 2020, 23 (10) :1286-1291
[28]   Depression Symptoms Predict Worse Clinical Response to Etanercept Treatment in Psoriasis Patients [J].
Jin, Waishu ;
Zhang, Shuqing ;
Duan, Yanjuan .
DERMATOLOGY, 2019, 235 (01) :55-64
[29]   Antidepressant activity of anti-cytokine treatment: a systematic review and meta-analysis of clinical trials of chronic inflammatory conditions [J].
Kappelmann, N. ;
Lewis, G. ;
Dantzer, R. ;
Jones, P. B. ;
Khandaker, G. M. .
MOLECULAR PSYCHIATRY, 2018, 23 (02) :335-343
[30]   Long-term experience with apremilast in patients with psoriatic arthritis: 5-year results from a PALACE 1-3 pooled analysis [J].
Kavanaugh, Arthur ;
Gladman, Dafna D. ;
Edwards, Christopher J. ;
Schett, Georg ;
Guerette, Benoit ;
Delev, Nikolay ;
Teng, Lichen ;
Paris, Maria ;
Mease, Philip J. .
ARTHRITIS RESEARCH & THERAPY, 2019, 21